AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01526863 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HA egg
Description: Daily dose of HA egg or placebo for 6 months
Study NCT01526863 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: HA egg
Description: Daily dose of HA egg or placebo for 6 months
Study NCT01615484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™
Description: After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™, and taken to UNCH where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNC Hospitals and Duke University Medical Center based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice.
Study NCT01615484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STEEN Solution™
Description: This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs.
Study NCT01352715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Lopinavir 400mg/ritonavir 100mg (given as two LPV 200mg/RTV 50mg fixed-dose combination tablets) orally twice daily, with or without food, throughout follow-up.
Study NCT01352715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Lopinavir 400mg/ritonavir 100mg (given as three LPV 133.3 mg/RTV 33.3 mg fixed-dose combination soft gelatin capsules) orally twice daily, with food, throughout follow-up.
Study NCT01352715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400 mg tablet orally twice daily, with or without food, throughout follow-up.
Study NCT01352715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
Study NCT01352715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine/zidovudine
Description: Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
Study NCT01352715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine
Description: Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
Study NCT01352715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine/zidovudine
Description: Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
Study NCT01352715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir
Description: Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily, with or without food, throughout follow-up.
Study NCT01352715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Zidovudine 300 mg tablet orally twice daily, with or without food, throughout follow-up.
Study NCT01352715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine 150 mg tablet orally twice daily, with or without food, throughout follow-up.
Study NCT02293148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Description: Oblong, dull red, film-coated, convex tablets with M400 on one side
Study NCT02293148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching GSK1278863
Description: A round, biconvex, white film coated tablet as matching placebo for GSK1278863
Study NCT02293148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Moxifloxacin
Description: Capsule shaped white film coated tablet as matching placebo for Moxifloxacin
Study NCT02635360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg of study drug is given through intravenous (IV) administration once every 21 days for 3 months.
Study NCT02635360 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Radiation is done for standard clinical care purposes.
Study NCT02635360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40 mg of chemotherapy drug will be given weekly for 5-6 weeks.
Study NCT02268474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 532nm KTP Laser vs 595nm Pulse Dye Laser
Description: Intervention for the Cutera Excel V system is to cease treatment to any subject that is experiencing any adverse reaction.
Study NCT00666523 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phytalgic
Description: 3/day
Study NCT00666523 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3/Day
Study NCT03742284 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SoftOx Wound Irrigation Solution
Description: The SoftOx Wound Irrigation Solution is a Medical device that contains a combination of hypochlorous acid and acetic acid in purified water. SWIS is primary intended for mechanical irrigation of acute wounds whereas hypochlorous acid acts as a ancillary medicinal (drug) substance with potential antimicrobial effects.~Acute wounds will be rinsed according to protocol and safety (AEs/ADEs/SAEs/SADEs) is the primary objective.
Study NCT04265313 — intervention group
Intervention type: OTHER
Intervention: Measurement of Quality of Life
Description: Quality of life will be measured using The Neck Dissection Impairment Index, Modified Constant-Murley Score, Short Form-36 Health Survey version-2.0.
Study NCT02705287 — intervention group
Intervention type: OTHER
Intervention: Vitamin D dynamics-pregnant
Description: tracer dose of deuterated vitamin D3
Study NCT02705287 — intervention group
Intervention type: OTHER
Intervention: Vitamin D dynamics-nonpregnant
Description: tracer dose of deuterated vitamin D3
Study NCT01719926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: 3 times per day from 2 days before until 5 days after chemotherapy. Escalating dosage each cohort.
Study NCT03296033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: The intervention is the implementation of a 36-hour time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing.
Study NCT03296033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: This is the historical control arm. 24 hours removed from their last dose (time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing)
Study NCT04121195 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dose escalation
Description: The trial will enrol virologically suppressed HIV infected volunteers who are stable on ATV/r and 2 NRTI containing ART following stringent screening to rule out evidence of renal, hepatic or gastrointestinal dysfunction which may affect the PK evaluation. A steady-state PK (PK1) sample collection shall be done on day 7 (+/-3) after enrolment. RIF will be added at standard dose (600 mg once daily) with a further PK evaluation 14 days later (PK2); due to the potential risk of sub therapeutic PI concentrations and emergence of HIV drug resistant strains, these individuals will be given DTG 50 mg twice daily for the duration of the dose-escalation study. ATV/r dose will be increased in a single step to the total modelled dose (PK3), given as twice daily doses. Once at maximum ATV/r dose, RIF will be increased to 1200 mg once a day for a further seven days (PK4). RIF will then be stopped, ATV/r stepped down to 300/100mg once a day and DTG continued for a further one week.
Study NCT02550470 — intervention group
Intervention type: DEVICE
Intervention: Carbon Dioxide Absorbents
Description: Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
Study NCT02550470 — intervention group
Intervention type: DEVICE
Intervention: Micropore SpiraLith
Description: lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.
Study NCT02550470 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Study NCT01706887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Amiloride
Description: only arm of the trial
Study NCT02098785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine citrate
Description: Oral solution
Study NCT01310452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: insulin detemir once daily with metformin
Study NCT02315352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-PZQ ODT
Description: L-PZQ ODT (MSC2499550A) tablet at a dose of 150 milligram (mg) put and disintegrated in the mouth without water
Study NCT02315352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rac-PZQ ODT
Description: Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg put and disintegrated in the mouth without water
Study NCT02315352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-PZQ ODT
Description: L-PZQ (MSC2499550A) tablet at a dose of 150 mg dispersed in water
Study NCT02315352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rac-PZQ ODT
Description: Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg dispersed in water
Study NCT02315352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cesol®
Description: Cesol® tablet at a dose of 150 mg crushed in water
Study NCT02071667 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Study NCT00610103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: apomorphine hydrochloride
Description: Apomorphine hydrochloride (started at 1 mg and titrated to a maximum of 6 mg) is subcutaneously administered.
Study NCT00610103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: apomorphine hydrochloride
Description: Apomorphine hydrochloride (started at 1 mg and titrated to a maximum of 6 mg) is subcutaneously administered.
Study NCT00210470 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IRX-2
Description: IRX-2 for 10 days (2 s.c. injections of 1 mL each day) into bilateral mastoid insertion regions.
Study NCT00210470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Single i.v. injection of low-dose (300 mg/m2) on Day 1
Study NCT00210470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: 21 days of oral indomethacin, 25 mg. 3 times daily
Study NCT00210470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: 21 days of zinc gluconate (65 mg) as part of an oral multivitamin
Study NCT00210470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 21 days of 20 mg. orally
Study NCT03503253 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Interlock-35 Fibered IDC Occlusion System
Description: Use of detachable coil for LAA leak closure
Study NCT03503253 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Concerto Helix Detachable Coil System
Description: Use of detachable coil for LAA leak closure
Study NCT03503253 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Azur Peripheral Coil System
Description: Use of detachable coil for LAA leak closure
Study NCT01008293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: VSL#3 (2 capsules bid.for 2 months, Each containing 112.5 billion viable lyophilized bacteria). Each capsule contains 4 strains of Lactobacillus (L. casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacterium (B. longum, L. breve, and B. infantis), and 1 strain of Streptococcus salivarius subsp. thermophilus (designated hereafter as S. thermophilus)
Study NCT01008293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: 30-60 ml of lactulose per day for 2 months to ensure 2-3 soft stools.
Study NCT01003574 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: lifestyle modification and telephone counseling
Description: A mailed individualized cancer treatment summary with recommendations for CV follow-up and lifestyle modification (standard care).
Study NCT01003574 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: lifestyle modification and telephone counseling
Description: Standard care plus motivational, autonomy-supportive APN counseling (2 phone sessions) that targets two categories of behavioral constructs likely to influence screening.
Study NCT02867293 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided ascitic fluid drainage
Study NCT02867293 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: operative drainage of ascites through small skin incision after induction of anesthesia
Study NCT02867293 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Study NCT00948142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEM-102
Description: 600 mg BID oral tablets for 10-14 days
Study NCT01310452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neutral protamine insulin
Description: neutral protamine insulin once daily with metformin
Study NCT02386397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment
Study NCT02386397 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GEMOX
Description: mGEMOX: infusion on days 1 and 8: Gemcitabine 900 mg/m² IV in 30 minutes Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine
Study NCT02386397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMOX
Description: mGEMOX: infusion on days 1 and 8: Gemcitabine 900 mg/m² IV in 30 minutes Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine
Study NCT02481674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX15/2503
Description: VX15/2503 (pepinemab) is a humanized IgG4 monoclonal antibody and will be administered intravenously at a dose of 20 mg/kg. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
Study NCT02481674 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
Study NCT00765206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole/sodium bicarbonate
Description: Single dose of omeprazole/sodium bicarbonate per day for either 1 or 7 days.
Study NCT00765206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole magnesium (20 mg equivalent)
Description: Single dose of omeprazole magnesium per day for either 1 or 7 days.
Study NCT04046809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food for special medical purposes: Neurotidine®
Description: Each patient will be given the bottles for the first 3-month treatment period by the hospital pharmacist and will be asked to return them at the end of the period (3 months). Then the patients will be given the other bottles for the next phase of the study (3 months): these will contain placebo if the patient received Neurotidine® in the first phase of the study and vice versa. Again, the patients will be asked to return after 3 months with the study bottles and will be given the last set of bottles for the final phase of the study (3 months).~Administration at a dosage of 10 ml in the morning.
Study NCT04046809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each patient will be given the bottles for the first 3-month treatment period by the hospital pharmacist and will be asked to return them at the end of the period (3 months). Then the patients will be given the other bottles for the next phase of the study (3 months): these will contain placebo if the patient received Neurotidine® in the first phase of the study and vice versa. Again, the patients will be asked to return after 3 months with the study bottles and will be given the last set of bottles for the final phase of the study (3 months).~Administration at a dosage of 10 ml in the morning.
Study NCT00871975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urodynamics + TETRA - NIRS
Description: Urodynamics will be performed as per standard of care for patients enrolled, whereby one catheter is inserted into the bladder and one in the rectum to analyze bladder filling, storage and voiding conditions via pressures measured and urine flow rates detected by a uroflowmeter. Tetra-NIRS will be concurrently performed where Tetra-NIRS unit uses near infrared light at 3 different wavelengths to measure changes in haemoglobin and cytochrome. A patch is applied externally to measure these changes in the detrusor muscle of the human bladder wall. This process is similar to what is used for cerebral and muscle oxygenation monitoring (e.g., pulse oximetry). Previous clinical feasibility studies have identified a correlation between the changes in haemoglobin and cytochrome and the pressure values obtained during urodynamics procedures.
Study NCT03850756 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Early kidney damage biomarkers
Description: In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured.
Study NCT00948142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: 600 mg BID oral tablets
Study NCT00948142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEM-102
Description: 1500 mg BID oral tablets on Day 1 followed by 600 mg BID oral tablets for a total of 10-14 days
Study NCT03850756 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Predisposition to kidney injury biomarkers
Description: In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured.
Study NCT03850756 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tobacco consumption
Description: In order to know the degree of tobacco consumption, the biomarker cotinine will be measured in the urine samples of these patients.
Study NCT01476774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine Transdermal System
Description: Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.~maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control .
Study NCT04349267 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986315
Description: Specified dose on specified days
Study NCT04349267 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on specified days
Study NCT04349267 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Specified dose on specified days
Study NCT03592186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Wisely+
Description: Parenting Wisely+ experimental intervention
Study NCT03592186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Treatment as Usual
Study NCT03592186 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual
Study NCT04062630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFuse 3-D in Bedrock Configuration
Description: Procedure in which 3 or more spinal segments are fused and concomitant pelvic fixation is performed, additionally iFuse 3-D implants are placed in a trajectory parallel to the S2AI screws.
Study NCT04062630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multilevel Lumbar Fusion surgery
Description: Procedure in which 3 or more spinal segments are fused and concomitant pelvic fixation is performed.
Study NCT04062630 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multilevel Lumbar Fusion surgery
Description: Procedure in which 3 or more spinal segments are fused and concomitant pelvic fixation is performed.
Study NCT01069003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Description: Placebo and ASA (75 mg - 325 mg)
Study NCT01069003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thienopyridine Therapy
Description: Prasugrel 5 or 10 mg or Clopidogrel 75 mg plus ASA (75 mg - 325 mg)